Products

CorVista System with PH Add-On
Analytics for Life
Cardiology AI
The CorVista System with PH Add-On is an FDA-cleared, non-invasive, point-of-care AI diagnostic platform for rapid assessment of coronary artery disease and pulmonary hypertension using machine-learned algorithms.

See all 1 product →

About Analytics for Life

Analytics 4 Life is a digital health company at the forefront of developing next-generation, non-invasive diagnostic solutions for cardiovascular diseases. Their flagship product, the CorVista System®, is an Rx-only, point-of-care solution designed to assess symptomatic patients for conditions such as Coronary Artery Disease (CAD) and pulmonary hypertension (PH). The system utilizes machine learning to synchronously collect and analyze cardiac and hemodynamic signals, providing physicians with a rapid assessment without the need for radiation, contrast agents, injections, fasting, or exercise.

Within minutes of the test, the CorVista Analysis is made available through a secure web portal, offering crucial insights to aid physicians in diagnosing patients and guiding treatment decisions. The CorVista System, including its CAD and PH Add-Ons, has received FDA clearance for marketing within the United States. Analytics 4 Life is responsible for the development and manufacturing of the CorVista System, which is then licensed to CorVista Health, Inc. for commercialization.

What Physicians Need to Know

Specialized Cardiovascular Diagnostics
Analytics For Life specializes in pioneering non-invasive diagnostic solutions for cardiovascular diseases, including coronary artery disease (CAD), pulmonary hypertension (PH), and heart failure (HFpEF, HFrEF) through its CorVista Systemu00ae.
AI-Powered Analysis
The company leverages advanced machine learning algorithms to quickly analyze intrinsic heart signals, providing rapid diagnostic insights.
Regulatory Achievements
The CorVista Systemu00ae has received U.S. FDA clearance for coronary artery disease (September 2023) and pulmonary hypertension (April 2024), with the PH indication also awarded an FDA Breakthrough Device Designation.
Non-Invasive Point-of-Care
Their technology offers a non-invasive, point-of-care test that can assess symptomatic patients for cardiovascular disease without the need for radiation, contrast agents, injections, fasting, or exercise.
Physician Tip

For physicians, Analytics For Life's CorVista Systemu00ae stands out by offering a rapid, non-invasive method for assessing critical cardiovascular conditions. This significantly reduces patient discomfort and eliminates risks associated with traditional invasive procedures, radiation exposure, or contrast agents. The system delivers results in under 30 minutes to a secure physician web portal, providing a unique image and heart model that, when combined with a patient's medical history, risk factors, and symptoms, aids in comprehensive assessment and guides timely treatment decisions in a single visit. This approach can be a game-changer for early detection of conditions like HFpEF, HFrEF, and PH, streamlining the diagnostic pathway and improving patient care.

The CorVista Systemu00ae is developed by Analytics For Life and commercialized in the U.S. by CorVista Health. Results are displayed on a secure physician web portal, indicating a direct access point for healthcare providers. While the provided information highlights the delivery of results to a web portal, specific details regarding integrations with Electronic Health Records (EHRs) or other hospital information systems are not explicitly mentioned in the available news release.

Products by Analytics for Life

1 product in the directory

CorVista System with PH Add-On
Analytics for Life
Cardiology AI
The CorVista System with PH Add-On is an FDA-cleared, non-invasive, point-of-care AI diagnostic platform for rapid assessment of coronary artery disease and pulmonary hypertension using machine-learned algorithms.

Reviews & Opinions

No web reviews on file yet for Analytics for Life. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Analytics for Life.

Loading videos...

Videos load interactively. If none appear, search YouTube for Analytics for Life →

View all on YouTube

Press & Coverage

GlobeNewswire
Analytics For Life Completes Clinical Study of Non-Invasive Point-of-Care Test for Elevated Pulmonary Capillary Wedge Pressure (PCWP) Using Machine Learning
Analytics for Life announced the completion of a clinical study for its non-invasive, point-of-care test using machine learning to detect elevated pulmonary capillary wedge pressure (PCWP). This test aims to improve the diagnosis and management of heart failure and pulmonary hypertension.
2025-08
Business Wire
Analytics for Life and CorVista Health Announce the Publication of their Cost Economic Analysis for Non-Invasive Coronary Artery Disease Testing in the Journal of Visualized Experiments
Analytics for Life and CorVista Health published a cost economic analysis in the Journal of Visualized Experiments (JoVE) for their non-invasive point-of-care test for Coronary Artery Disease (CAD). The analysis highlights the economic benefits and seamless integration of the CorVista System into existing CVD diagnostic workflows.
2024-08
Journal of the American College of Cardiology (JACC): Heart Failure
Validation of a Non-invasive Machine Learning Algorithm to Assess Elevated Pulmonary Capillary Wedge Pressure at Point-of-Care
This abstract details the validation of a non-invasive machine learning algorithm to estimate pulmonary capillary wedge pressure (PCWP) at the point of care, showing robust performance in identifying PCWP elevation. The study suggests clinical utility for diagnosing heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH).
2025-11
Pulmonary Hypertension News
Corvista point-of-care device good at detecting heart failure: Study
A study found that CorVista Health's point-of-care device, utilizing machine learning, effectively detects elevated pulmonary capillary wedge pressure (PCWP), indicating its potential for non-invasive heart failure diagnosis. The device showed high sensitivity and specificity in identifying patients with heart failure.
2025-04
PubMed (JACC Heart Fail.)
Noninvasive Pulmonary Capillary Wedge Pressure Estimation in Heart Failure Patients With the Use of Wearable Sensing and AI
This study explores a noninvasive technology using a wearable sensor (CardioTag) and machine learning for estimating pulmonary capillary wedge pressure (PCWP) in heart failure patients. The model demonstrated accuracy comparable to implantable sensors, offering a potentially more accessible and cost-effective management option.
2025-06
Fierce Biotech
Analytics 4 Life nets $25M for AI-based cardiac diagnostic
Analytics 4 Life secured $25 million in Series B financing to advance its noninvasive, AI-based CorVista platform for diagnosing coronary artery disease. The funding will support clinical trials and regulatory clearance for the device, which aims to provide a faster and safer diagnostic method.
2017-09
DAIC
Analytics 4 Life Raises $25 Million for AI-Backed Cardiac Imaging Technology
Digital health company Analytics 4 Life completed a $25 million Series B financing round to further develop its AI-backed cardiac imaging technology, CorVista. The technology is designed to non-invasively assess coronary artery disease using intrinsic body signals.
2017-10
accessdata.fda.gov
Analytics for Life, Inc. K233666
This FDA 510(k) premarket notification indicates that Analytics for Life, Inc. received clearance for its CorVista System with PH Add-On, classified as a Cardiovascular Machine Learning-Based Notification Software. The device is intended to aid in the diagnosis of elevated mean pulmonary arterial pressure.
2023-11

Frequently Asked Questions

Analytics for Life primarily offers the CorVista System, a non-invasive, point-of-care solution that uses machine learning and AI to assess symptomatic patients for cardiovascular diseases like Coronary Artery Disease (CAD) and Pulmonary Hypertension (PH). This system aims to provide rapid diagnostic insights without radiation or contrast agents, with results available in minutes via a secure web portal.
Analytics for Life emphasizes privacy, data transparency, and governance in its operations. Their CorVista System, an Rx-only device, has received FDA clearance for marketing in the U.S. for its CAD and PH Add-Ons, indicating adherence to stringent regulatory standards for medical devices.
While specific pricing models are not publicly detailed, Analytics for Life has published cost economic analyses demonstrating that adopting the CorVista System can be economically beneficial, offering significant cost savings to the healthcare system. These savings are achieved by preventing loss to follow-up and reducing the need for more expensive, invasive diagnostic procedures.
Although specific details on support plans are not extensively publicized, successful adoption of healthcare AI solutions typically involves comprehensive implementation support, training, and ongoing technical assistance. Analytics for Life's focus on point-of-care diagnostics suggests a need for robust support to seamlessly integrate their system into existing clinical workflows.
Analytics for Life's CorVista System is designed to integrate seamlessly into current cardiovascular diagnostic workflows. They have an exclusive commercial partnership with CorVista Health for the introduction of their system in the United States, and their broader 'Analytics for Living' entity has engaged with various life science manufacturers, health providers, and government health systems.
Founded in 2012, Analytics for Life (also known as Analytics 4 Life) has a track record of developing AI-driven diagnostic solutions, including securing $25 million in Series B financing in 2017. The company continues to be active, evidenced by recent clinical study completions and publications in 2024 and 2025, demonstrating ongoing product development and market engagement.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.